Results of @entity3895 regimen (CCNU, melphalan, and XXXX ) as third-line salvage therapy for @entity978 .

@entity1 @entity137 @entity66 @entity548 @entity2879 @entity281 @entity978 @entity3043 @entity3895
BACKGROUND: A prospective study was conducted to assess the efficacy and @entity137 of a salvage regimen consisting of CCNU, Melphalan, and @entity2879 ( @entity3895 ) given at 28-day intervals in @entity1 with @entity978 ( @entity978 ) relapsing after primary therapy or refractory to the alternating MOPP/ABVD regimen. @entity1 AND METHODS: This study included 58 @entity1 (median age: 34 years), with resistant or relapsing @entity978 . Primary therapy had consisted of alternating MOPP/ABVD (81%) or MOPP alone (19%); 38% of @entity1 were relapsing from prior complete remission (CR) while 62% had resistant disease. @entity66 was present in 55% and B-symptoms in 72% of @entity1 ; one-fifth had bulky disease and/or bone marrow involvement. The @entity3895 was used as first salvage in half of the @entity1 . RESULTS: Complete remission was obtained in 17 @entity1 (29%); unfavorable factors for CR in univariate analysis were the presence of bulky disease and the failure to achieve CR with prior therapy. Nine @entity1 (53% of remitters) have subsequently relapsed with a 10-month median duration of CR. The 3-year overall survival after @entity3895 was 25% with an 18-month median survival; significant differences in survival were found according to the extent of disease, the presence of B-symptoms and the @entity978 status (prior sensitive or resistant disease, first or subsequent relapse). Seven @entity1 are long-term remitters (12%), and one of them has been given high-dose chemotherapy and autologous bone marrow transplantation at relapse after @entity3895 . The @entity3895 @entity137 was mostly hematological; severe @entity3043 occurred in six cases with two cases of @entity281 and one of fatal @entity548 . CONCLUSION: @entity3895 therapy was moderately effective as third-line salvage in @entity1 with @entity978 resistant to alternating MOPP/ABVD or previously given two different regimens for relapse; the @entity137 was mostly hematological and supportive therapy was needed in one-third of the @entity1 .
